Clinical Trial Update: Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations [Phase 1]

View source ↗

Summary

Hutchmed is conducting a Phase I trial of HMPL-306 for gliomas with IDH1 and/or IDH2 mutations, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• HMPL-306

Snippet

Sponsor: Hutchmed | Conditions: Gliomas Harboring IDH1 and/or IDH2 Mutations | Phase 1 | Status: RECRUITING